Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics" but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarter ended July 31, 1996 (Form 10-Q)
Status: Development Stage Enterprise; Pre-clinical trial stage.
Operations: The company is developing synthetic blood products requiring FDA approval. It has no principal operations or revenue-generating sales yet.
Key Financial Metrics
| Metric | Three Months Ended July 31, 1996 | Three Months Ended July 31, 1995 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(617,406) | $(345,190) |
| Accumulated Deficit | $(6,630,002) | $(6,376,756) |
| Cash and Equivalents (End of Period) | $153,618 | $157,477 |
| Working Capital | $(336,868) | Not explicitly stated |
| Total Current Liabilities | $503,961 | $974,969 (Prior Quarter) |
| Stockholders' Equity (Deficit) | $(78,207) | $(597,603) (Prior Quarter) |
Note: The filing text contains conflicting data between the "Statements of Operations" table (showing a $6.6M loss for the quarter) and the "Management's Discussion and Analysis" (showing a $617,406 loss for the quarter). The MD&A figure is used above as it aligns with the cash flow reconciliation and typical quarterly reporting for a development stage company.
Material Changes vs. Prior Period
- Expense Increase: Net loss increased from $345,190 to $617,406.
- R&D Expenses: Rose to $279,180 (from $173,054) due to increased personnel, animal acquisition, and outside lab testing.
- G&A Expenses: Rose to $336,814 (from $182,554) driven by a non-recurring $326,000 charge related to a standby funding agreement and financing commissions.
- Liability Reduction: Total current liabilities decreased significantly from $974,969 (April 30, 1996) to $503,961 (July 31, 1996). This was largely due to the conversion of $581,763 in stockholder loans and unpaid salaries into common stock.
- Equity Improvement: Stockholders' deficit improved from $(597,603) to $(78,207) due to equity issuances and debt conversions.
Outlook, Risks, and Management Commentary
- Going Concern: Management states substantial doubt exists regarding the company's ability to continue as a going concern. Continued operations depend on obtaining additional financing for Phase I, II, and III clinical trials.
- Liquidity: The company reported a working capital deficit of approximately $394,000 (per MD&A) or $336,000 (calculated from balance sheet). Cash on hand is $153,618.
- Financing Activities: The company raised funds through the sale of common stock ($5.18M accumulated during development stage, with specific recent issuances to Caymus Capital Ltd. and for debt conversion).
- Issued 1,000,000 shares to Caymus Capital Ltd. for $200,000.
- Issued 2,869,191 shares to officers/directors to cancel $581,763 in loans/expenses.
- Commitments: Future employment commitments total $411,000 for 1997 and $272,000 for 1998. Royalty agreements require minimum annual payments ranging from $30,000 to $200,000.
- Risks: No assurance of FDA approval or ability to secure necessary funding. Products are pre-clinical.
Investor Verification Checklist
- Revenue Reality: Verify the company has zero revenue and is entirely dependent on capital raises.
- Cash Runway: Assess if the $153,618 cash balance is sufficient to cover the $411,000+ in committed employment costs and R&D for the upcoming year.
- Dilution Risk: Review the recent issuance of nearly 4 million shares (1M to Caymus, 2.8M for debt conversion) and its impact on existing shareholder value.
- Debt Conversion: Confirm the terms of the $581,763 debt converted to equity to ensure no hidden liabilities remain.
- Going Concern Status: Evaluate the likelihood of securing the "significant additional financing" required for clinical trials.